Literature DB >> 16720208

Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies.

Cynthia M Magro1, W James Waldman, Deborah A Knight, James N Allen, Tibor Nadasdy, Gwyn E Frambach, Patrick Ross, Clay B Marsh.   

Abstract

Mechanisms underlying idiopathic pulmonary fibrosis are not well understood. This paper presents data supporting the hypothesis that microvascular endothelial cell injury and antiendothelial cell antibodies play roles in human idiopathic pulmonary fibrosis. Serologic and pathologic features of 40 patients diagnosed with idiopathic pulmonary fibrosis were evaluated. All patients had open lung biopsies indicating either usual or nonspecific interstitial pneumonitis. All biopsies had morphologic evidence of microvascular injury to the endothelium, and direct immunofluorescence testing revealed variable deposition of IgG, IgM, or IgA within septal microvasculature suggestive of humorally mediated microvascular injury. Ultrastructural studies revealed changes of endothelial cell injury and necrosis and evidence of repetitive episodes of microvascular injury characterized by basement membrane zone collagen deposition and lamellation. Serum samples demonstrated reactivity to multiple endothelial cell antigenic epitopes, and indirect immunofluorescent testing demonstrated a prominent pattern of fluorescence in pulmonary endothelial cell preparations. Serum samples were positive in 37/40 patients for antiphospholipid antibodies with one fourth having positive lupus anticoagulant tests accompanied by thrombotic episodes. In patients with idiopathic pulmonary fibrosis, Factor VIII levels and C-reactive protein levels were also elevated, supporting the presence of endothelial cell injury and inflammation. These data underscore a potential role for immune-based microvascular injury in the evolution of usual or nonspecific interstitial pneumonitis and indicate that those patients have evidence of microvascular injury and endothelial cell necrosis. The high prevalence of antiphospholipid antibodies in these patients may lead to an inherent thrombophilic tendency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720208     DOI: 10.1016/j.humimm.2006.02.026

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  39 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  Serum analysis of coagulation factors in IPF and NSIP.

Authors:  E Bargagli; C Madioni; N Bianchi; R M Refini; R Cappelli; P Rottoli
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

3.  Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury.

Authors:  Heather G Leach; Izabela Chrobak; Rong Han; Maria Trojanowska
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

Review 4.  Coagulation and autoimmunity in scleroderma interstitial lung disease.

Authors:  Anna Ludwicka-Bradley; Richard M Silver; Galina S Bogatkevich
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

5.  Inhibitor of differentiation 1 promotes endothelial survival in a bleomycin model of lung injury in mice.

Authors:  Huimin Zhang; William E Lawson; Vasiliy V Polosukhin; Ambra Pozzi; Timothy S Blackwell; Ying Litingtung; Chin Chiang
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Kyung-Hee Kim; Fabien Maldonado; Jay H Ryu; Patrick W Eiken; Thomas E Hartman; Brian J Bartholmai; Paul A Decker; Eunhee S Yi
Journal:  Respir Res       Date:  2010-04-14

7.  CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.

Authors:  Syed R Gilani; Louis J Vuga; Kathleen O Lindell; Kevin F Gibson; Jianmin Xue; Naftali Kaminski; Vincent G Valentine; Emily K Lindsay; M Patricia George; Chad Steele; Steven R Duncan
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

8.  Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.

Authors:  Jianmin Xue; Daniel J Kass; Jessica Bon; Louis Vuga; Jiangning Tan; Eva Csizmadia; Leo Otterbein; Makoto Soejima; Marc C Levesque; Kevin F Gibson; Naftali Kaminski; Joseph M Pilewski; Michael Donahoe; Frank C Sciurba; Steven R Duncan
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

Review 9.  Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.

Authors:  Robert Brownell; Naftali Kaminski; Prescott G Woodruff; Williamson Z Bradford; Luca Richeldi; Fernando J Martinez; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2016-06-01       Impact factor: 21.405

Review 10.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Benjamin D Bringardner; Christopher P Baran; Timothy D Eubank; Clay B Marsh
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.